Announcement PDF ASX AND MEDIA RELEASE Race Oncology moves closer to Bisantrene launch: Signs NPP partnership with CarthaGenetics in Europe 5 September 2016, Perth, Australia: Race Oncology Limited (ASX: RAC) announced today that it had signed an agreement with the Swiss company, CarthaGenetics, to expedite the launch of the Company’s Named Patient Program in Europe, and to distribute and sell Bisantrene under the program. Under the agreement, CarthaGenetics will be responsible for market development and awareness of Bisantrene prior to launch and all necessary regulatory approvals to allow Bisantrene to be sold in each target NPP country. CarthaGenetics will also be responsible for all storage, distribution, invoicing, sales and customer service of Bisantrene in each country under the Named Patient Program. Under the agreement, Race Oncology will pay CarthaGenetics for certain fixed monthly costs and a commission on sales. “CarthaGenetics are experts in Named Patient Program sales in Europe,” said Managing Director, Peter Molloy. “Their expertise will help ensure Bisantrene gets to market rapidly and achieves its full sales potential.” The agreement will also provide Race with all the infrastructure and logistical support needed to sell Bisantrene in various European countries. CarthaGenetics CEO, Philippe Carteron de Balmont, said: “At CarthaGenetics, we are proud to help Race Oncology launch Bisantrene and achieve success in the European market. Named Patient access regulations in individual European countries allow patients access to innovative therapies under development. Given Bisantrene’s safety profile and clinical data, it is well-suited to a named patient sales program in those countries”. In all markets outside Europe, Race Oncology is now actively pursuing licensees for Bisantrene. To that end, Peter Molloy will be attending the Biopharm America conference in Boston on 13-15 September (www.biopharminsight.com/events/biopharm-america-2016) to engage with a host of potential licensing partners from around the world. About CarthaGenetics Based in Switzerland, CarthaGenetics® is a specialist in arranging and managing early access and named patient sales programs in Europe. CarthaGenetics helps international companies involved in Orphan Drug development to introduce products successfully into the complex European market, by coordinating all local regulatory approvals, distribution, invoicing and sales for its clients. CarthaGenetics has a direct presence in Switzerland, France, Germany, Spain, Italy, Poland, Turkey, Algeria and Tunisia, with local experts who are familiar with the each market’s regulatory Race Oncology Limited, ABN 61 149 318 749 Level 2, 50 Kings Park Road, West Perth WA 6005 www.raceoncology.com requirements and market success factors. CarthaGenetics has an impressive list of biotech and pharmaceutical clients, including Pfizer, Shire and Genzyme. Visit www.carthagenetics.com/namedpatient-sales/ for more information. About Race Oncology Race Oncology Limited is a specialty pharmaceutical company, whose business model is to pursue later stage assets, principally in the cancer field. The Company’s first important asset is a chemotherapy drug, called Bisantrene, which was the subject of more than 40 phase II clinical studies during the 1980s and 1990s. Race Oncology owns recent patent filings on Bisantrene and has secured Orphan Drug Designation in the US. The Company’s goal is to complete final development of Bisantrene and bring this valuable cancer drug to market. Visit raceoncology.com for more information. For more information, contact: Peter Molloy Managing Director T: +61 (0) 3 9097 1656 M: +61 (0) 418 174 816 Race Oncology Limited, ABN 61 149 318 749 Level 2, 50 Kings Park Road, West Perth WA 6005 www.raceoncology.com